BioNTech : Annual Report 2023 with the Consolidated Financial Statements as of 31 December 2023, the Combined Management Report for BioNTech SE and the Group and the Report of the Supervisory Board for the 2023 financial year

23

A C T I N G

T O G E T H E R

BioNTech | Annual Report 2023

2

1MAGAZINE

05

41

48

05	11	14	18	25	30	41	48	60
EXPLORING	OUR PIPELINE	FACTS AND	LETTER	INTERVIEW WITH	REPORT OF THE		FROM FOUNDING	2023 HIGHLIGHTS FINANCIAL
THE POWER OF		FIGURES	FROM THE	HELMUT JEGGLE	SUPERVISORY		VISION TO	CALENDAR,
COMBINATION			MANAGEMENT	AND UGUR SAHIN	BOARD		GLOBAL IMPACT	IMPRINT
			BOARD

BioNTech | Annual Report 2023

3

2	3	4	INDEPENDENT
AUDITOR'S REPORT
CONSOLIDATED
FINANCIAL
STATEMENTS
INDEPENDENT
AUDITOR'S REPORT
5REMUNERATION
			REPORT

62	115	217	249
COMBINED MANAGEMENT	GROUP REPORT 2023	COMPENSATION REPORT	FURTHER INFORMATION
REPORT 2023		2023

FINANCIAL REPORT

BioNTech | Annual Report 2023

Bispecific antibodies are protein molecules that can bind two different targets, bringing closer for example the cancer cell to the immune cell. When in close proximity of the cancer cell, the immune cell could recognize and orchestrate its elimination.

4

MAGAZINE1

BioNTech | Annual Report 2023

5

EXPLORING THE POWER OF COMBINATION

Our vision for future precision cancer treatments: We are developing a unique therapy toolbox designed to act together and with the aim to improve outcomes for patients.

BioNTech | Annual Report 2023

6

1 THE CHALLENGE //

When a physician discusses a potential treatment plan with a patient who has just been diagnosed with cancer, they know that they will have to treat a disease with many different facets. Cancer cells are physically different from healthy cells in the body. Their shapes and properties are mutated and changed. They interact differently with their environment to grow abnormally and survive. And in each growing cycle, they have the potential to change further. The cells in the same tumor within the same patient can also be different. Medicine faces the challenge that every tumor is unique.

DNA MUTATION

DNA MUTATION

2 THE CONSEQUENCE //

As a consequence, a standard of care might work for one, but not another patient. In other cases, the constant changes of the tumor cells lead to a resistance to available treatments. What may have originally given good results and helped the patient might not work over time. For example, it is estimated that more than 90% ofmortalitiesin cancer patients can be attributed to chemotherapy resistance.

Helping patients and addressing unmet medical needs is what drives us at BioNTech every day. We have been spending years on better understanding tumors' differences as well as the immune system's mechanisms to develop potential cancer treatments. We believe that the limitations cannot be overcome by a single technology, but rather a therapy toolbox.

SHARED	CLDN6	PD-L1	HER-2	EPCAM	PATIENT-
TUMOR					INDIVIDUAL
TARGET					TUMOR
TPTE					TARGET

BioNTech | Annual Report 2023

3 OUR APPROACH //

Targeted therapies //

Cell therapies are designed to equip certain immune cells of the patients physically with structures (recep- tors), enabling them to recognize cancer cells and orchestrate their elimination.

Antibody-drug conjugates (ADCs) are designed to targetedly deliver a chemotherapy to tumor cells. Unlike traditional chemotherapy, cancer treatments with ADCs are designed to minimize the impact on healthy cells.

7

SELECTED TARGETS

HER-2CLDN6

We work on potential treatment approaches that aim to precisely target the specific tumor features by employing a different mechanism to tackle each feature. Our approach is to combine therapies - some investigational and some approved - with the aim of achieving better results compared to the current standard of care. This is why we are developing a suite of technologies which we call our oncology toolbox.

SELECTED TARGETS

SYNER

GY

SYNERGETIC

SPACE FOR

CURATIVE

APPROACHES

SYNERGY

	GY
R
E
N
SY

SHARED	PATIENT- INDIVIDUAL
TUMOR	TUMOR
TARGET TPTE	TARGET	mRNA vaccines//

Immuno-modulators //

SELECTED TARGETS

PD-L1EpCAM

mRNA vaccines are designed to teach the immune	Mono- and bispecific antibodies are designed to
system about features on the surface of cancer cells	modulate the activity of immune cells and in some
(targets), supporting immune cells to recognize and	cases cancer cells, enhancing the immune response
destroy them.	against cancer cells.

Simplified illustration

BioNTech | Annual Report 2023

investigational cell therapy

B NT211

8

We have been evaluating combinational therapies since 2014. Here is a selection of a few currently running clinical trials:

BNT211 //

The product candidate BNT211 combines a CAR-T cell therapy candidate with an mRNA vaccine candidate. For the CAR-T cell therapy candidate, patients' certain immune cells are equipped with a receptor to recognize the target protein CLDN6 and precisely attack cancer cells. The mRNA vaccine candidate encodes for CLDN6 and is designed to stimulate these CAR-T cells' persistence and functionality in the body, complementing the CAR-T cells in a synergistic manner. This approach is aimed at more efficient recognition and elimination of cancer cells. BNT211 is currently being evaluated in Phase 1/2 clinical trials in patients with germ cell tumors.

	Claudin-6 (CLDN6) is a surface protein expressed
	on multiple solid tumors such as ovarian cancer,
	sarcoma, testicular cancer, endometrial cancer
mRNA vaccine candidate	and gastric cancer.

BioNTech | Annual Report 2023

individualized mRNA vaccine candidate

BNT122 + CHECKPOINT INHIBITOR

checkpoint inhibitor

9

AUTOGENE CEVUMERAN/BNT1221

+ CHECKPOINT INHIBITOR //

This potential treatment approach combines two different molecules to fight cancer. The individualized mRNA vaccine candidate BNT122 is designed to provide immune cells with information about the patient's unique cancer cells and induce an immune response against the tumor. The checkpoint inhibitor is an antibody that keeps cancer cells from suppressing immune cells. This combinatory approach is intended to lead to a stronger and more specific immune response and elimination of cancer cells. BNT122 is currently being evaluated in Phase 2 clinical trials in patients with melanoma.

1. In collaboration with Genentech, a member of the Roche Group.